🔗 Permalink

Inventor profile of:

Gregory HINKLE

City:

Cambridge, Massachusetts

Country:

United States

Published Applications:

53

Last publication date:

2024-10-17

Top Assignees for applications by Gregory HINKLE

The entities that hold a legal rights for patent applications filed by inventor HINKLE Gregory:

ALNYLAM PHARMACEUTICALS, INC. 23 Cambridge, MA United States
NOVARTIS AG 10 Basel, Switzerland
Arrowhead Pharmaceuticals, Inc. 8 Pasadena, CA United States
ARROWHEAD RESEARCH CORPORATION 2 Pasadena, CA United States
Genzyme Corporation 1 Cambridge, MA United States

Recent patent applications by HINKLE Gregory

Gregory HINKLE from Cambridge, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-10-17

US20240344073A1

Chemistry; metallurgy

PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#2 | 2022-12-01

US20220380775A1

Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

#3 | 2022-02-03

US20220033825A1

Chemistry; metallurgy

POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF

#4 | 2022-01-06

US20220002734A1

Chemistry; metallurgy

POLYNUCLEOTIDE AGENTS TARGETING AMINOLEVULINIC ACID SYNTHASE-1 (ALAS1) AND USES THEREOF

#5 | 2021-12-30

US20210402007A1

Human necessities

POLYNUCLEOTIDE AGENTS TARGETING HYDROXYACID OXIDASE (GLYCOLATE OXIDASE, HAO1) AND METHODS OF USE THEREOF

#6 | 2021-10-28

US20210332367A1

Chemistry; metallurgy

KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#7 | 2021-10-14

US20210317458A1

Chemistry; metallurgy

POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF

#8 | 2021-10-14

US20210317452A1

Chemistry; metallurgy

SERPINA1 iRNA compositions and methods of use thereof

#9 | 2021-10-07

US20210310006A1

Chemistry; metallurgy

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

#10 | 2021-08-26

US20210261959A1

Chemistry; metallurgy

Complement component C3 iRNA compositions and methods of use thereof

#11 | 2021-08-12

US20210246447A1

Chemistry; metallurgy

Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#12 | 2021-07-29

US20210228614A1

Human necessities

LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#13 | 2021-07-22

US20210222176A1

Chemistry; metallurgy

POLYNUCLEOTIDE AGENTS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) AND METHODS OF USE THEREOF

#14 | 2021-06-24

US20210189391A1

Chemistry; metallurgy

Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

#15 | 2021-06-10

US20210171956A1

Chemistry; metallurgy

Glucokinase (GCK) iRNA compositions and methods of use thereof

#16 | 2021-04-15

US20210108203A1

Chemistry; metallurgy

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

#17 | 2021-04-01

US20210095290A1

Chemistry; metallurgy

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

#18 | 2021-03-25

US20210087218A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS

#19 | 2021-02-18

US20210046187A1

Human necessities

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

#20 | 2020-12-10

US20200384011A1

Human necessities

POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF

#21 | 2020-05-07

US20200140864A1

Chemistry; metallurgy

Hepatitis B virus (HBV) iRNA compositions and methods of use thereof

#22 | 2019-09-12

US20190276827A1

Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

#23 | 2019-01-17

US20190016751A1

Chemistry; metallurgy

Compositions and methods directed to treating liver fibrosis

#24 | 2018-12-13

US20180355362A1

Chemistry; metallurgy

Organic compositions to treat beta-ENaC-related diseases

#25 | 2018-09-27

US20180273947A1

Chemistry; metallurgy

Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

#26 | 2018-04-12

US20180100150A1

Chemistry; metallurgy

Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#27 | 2018-04-05

US20180092990A1

Human necessities

Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof

#28 | 2018-03-29

US20180087054A1

Chemistry; metallurgy

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#29 | 2017-12-07

US20170349901A1

Chemistry; metallurgy

Hepatitis D virus (HDV) iRNA compositions and methods of use thereof

#30 | 2017-12-07

US20170349900A1

Chemistry; metallurgy

Hepatitis B virus (HBV) iRNA compositions and methods of use thereof

#31 | 2017-11-30

US20170340661A1

Human necessities

Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof

#32 | 2017-11-16

US20170327829A1

Chemistry; metallurgy

Organic compositions to treat Beta-ENaC-related diseases

#33 | 2017-09-14

US20170260527A1

Chemistry; metallurgy

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

#34 | 2017-08-24

US20170240892A1

Chemistry; metallurgy

Polynucleotide agents targeting Serpinc1 (AT3) and methods of use thereof

#35 | 2017-07-20

US20170204418A1

Chemistry; metallurgy

Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof

#36 | 2017-06-29

US20170183659A1

Chemistry; metallurgy

Polynucleotide agents targeting complement component C5 and methods of use thereof

#37 | 2017-03-16

US20170073678A1

Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

#38 | 2016-09-22

US20160272979A1

Chemistry; metallurgy

Organic compositions to treat beta-ENaC-related diseases

#39 | 2015-10-08

US20150284721A1

Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

#40 | 2015-10-01

US20150275218A1

Chemistry; metallurgy

Organic compositions to treat beta-ENaC-related diseases

#41 | 2014-04-17

US20140107179A1

Chemistry; metallurgy

Organic compositions to treat Beta-ENaC-related diseases

#42 | 2014-04-10

US20140099666A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT

#43 | 2014-02-06

US20140039039A1

Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

#44 | 2014-01-02

US20140004565A1

Chemistry; metallurgy

CELL-BASED BIOPROCESSING

#45 | 2013-10-31

US20130289094A1

Chemistry; metallurgy

Compositions and Methods for Inhibition of PCSK9 Genes

#46 | 2013-01-10

US20130012571A1

Chemistry; metallurgy

Organic compositions to treat Beta-ENaC-related diseases

#47 | 2012-05-24

US20120129915A1

Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

#48 | 2012-05-24

US20120129914A1

Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

#49 | 2012-05-17

US20120122960A1

Chemistry; metallurgy

Organic compositions to treat Beta-ENaC-related diseases

#50 | 2012-05-10

US20120115934A1

Chemistry; metallurgy

Organic compositions to treat beta-ENaC-related diseases

#51 | 2012-05-10

US20120115933A1

Chemistry; metallurgy

Organic compositions to treat Beta-ENaC-related diseases

#52 | 2011-10-27

US20110263681A1

Chemistry; metallurgy

Organic compositions to treat beta-ENaC-related diseases

#53 | 2011-07-07

US20110166058A1

Chemistry; metallurgy

Organic compositions to treat HSF1-related diseases

InventorID:

30203 ⎘